New antibody drug shows promise in early arthritis trial

NCT ID NCT03574545

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tested two versions of an experimental drug called ianalumab in 48 adults with active rheumatoid arthritis. The goal was to see if the two forms are similar enough in safety and how the body processes them. Participants received multiple injections, and researchers tracked side effects and drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ianalumab (a lab-made antibody that targets B cells)
What this could lead to: If successful, this could help confirm that the two forms of ianalumab are similar enough to use in larger trials for rheumatoid arthritis.
What could go wrong: This is a very early Phase 1 study with only 48 people, focused on safety and drug levels, not on whether the drug actually improves arthritis symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

Contacts and locations

Locations

Novartis Investigative Site

Berlin, 10117, Germany
Novartis Investigative Site

Amman, 11941, Jordan

More trials for these conditions

Other studies related to the condition(s) this trial covers.